The NSMF Initiative: New Safe Medicines Faster
EFB Section on Medicines Development
NSMF relevant links
-
European Platform on Innovative Medicines
The overall objective of the platform is to remove bottlenecks hampering the efficiency of the development of new medicines, and where research is the key to resolve current obstacles for the European pharma/biotechnology industry to become world leaders. Industry is currently, together with relevant stakeholders (such as EMEA and national regulatory agencies, patient organisations, health care providers, health insurance and member states), developing a strategic research agenda identifying critical scientific gaps in which more pre-competitive research is urgently required. Such a platform at EU level will ensure the maximum utilization of resources and is expected to provide socio-economic benefits for the European citizens [e.g. delivery of health care (including health expenditure)], as well as contributing to the increased competitiveness of European pharma/biotech industry at large. -
FDA White paper, Innovation Stagnation: Challenge and Opportunity on the Critical Path to New Medical Products
On March 16, 2004, FDA released a report addressing the recent slowdown in innovative medical therapies submitted to the FDA for approval, "Innovation/Stagnation: Challenge and Opportunity on the Critical Path to New Medical Products." The report describes the urgent need to modernize the medical product development process -- the Critical Path -- to make product development more predictable and less costly. - The European Medicines Agency Road Map to 2010. Preparing the ground for the future.
- G10 Medicines, High Level Group on Innovation and the Provision of Medicines. Background and the final G10 Medicines report
You are welcome to inform us about other NSMF relevant links